Repros Therapeutics

Repros Therapeutics — Investor Presentation (September 2017)

16 slides from Repros Therapeutics's investor presentation, Sep 11, 2017

  1. Slide 1: Repros Therapeutics Corporate Presentation September 2017

    REPROS THERAPEUTICS Corporate Presentation September 2017 Dedicated to Treating Male and Female Reproductive Disorders

  2. Slide 2: Safe Harbor

    Safe Harbor Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties

  3. Slide 3: Company Overview and Recent Leadership Appointments

    Company Overview and Recent Leadership Appointments ■ Originally founded as Zonagen – an animal health company using technology from Baylor University ■ IPO 1993 ■ Key recent developments – Patrick Fourteau named as Chairman of the Board – Larry Dillaha, M.D. named President and CEO – Important pate

  4. Slide 4: Experienced Management Team

    Experienced Management Team ■ Larry Dillaha, M.D. – President and CEO (Feb 2017) – Sanofi, Sciele / Shionogi, Insys Therapeutics – History of clinical and regulatory success ■ Kathi Anderson, CPA – CFO – Joined Repros in 2002 – More than 15 years in biotech, life sciences ■ Joe Wernicke, M.D., Ph.D.

  5. Slide 5: Proellex (Telapristone Acetate) for Uterine Fibroids and Endometriosis

    Proellex ® (Telapristone Acetate) for the Treatment of Uterine Fibroids and Endometriosis ■ Licensed from NIH, 1999 ■ Selective Progesterone Receptor Modulator (SPRM) ■ No selectivity for glucocorticoid receptor need for chronic intermittent dosing ■ Lead indications: – Treatment of Uterine Fibroids

  6. Slide 6: Selective Progesterone Receptor Modulator (SPRM)

    Selective Progesterone Receptor Modulator (SPRM) ■ Evolved from progesterone antagonists – Mifepristone – Limited use because of high affinity for glucocorticoid receptor over progesterone receptor • Recognizing need for more selective progesterone receptor activity; SPRMs developed ■ Mixed agonist

  7. Slide 7: Uterine Fibroids

    Uterine Fibroids ■ Benign smooth muscle tumors of uterus (leiomyomas) ■ Most common tumor of female reproductive tract – 20 - 77% of women aged 35 - 55 ■ Quality of Life often impacted – Heavy menstrual bleeding – Discomfort and pain ■ Current Therapy – Medications • NSAIDS, OCPs, GnRH agonists, Pro

  8. Slide 8: Endometriosis

    Endometriosis ■ Endometrial tissue growing outside the uterus – Infertility – pain, including pelvic pain – Dyspareunia – Dysmenorrhea – 11% of women aged 15 - 44 – 25 - 40% of all cases of infertility – 71 - 87% of women with chronic pelvic pain – 53% teenagers with dysmenorrhea ■ Impact on QoL ■ C

  9. Slide 9: How Antiprogestins Like Proellex Work

    GnRH agonists and antagonists. These agents: • Block hypothalamus / pituitary axis • Shut down hormonal secretions • Add - back hormonal therapy Proellex ® Hypothalamus Pituitary Endometrial & Uterine Tissue Antiprogestins • Selectively block progesterone activity • Allow tonic hormone secretions -

  10. Slide 10: Proellex Effectiveness in Patients

    Proellex ® Effectiveness in Patients 10 AN EFFECTIVE ORAL DOSE OF PROELLEX ® STOPS MENSTRUATION (AMENORRHEA) IN MAJORITY OF WOMEN Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with

  11. Slide 11: Proellex Regulatory / Development History

    Proellex Regulatory / Development History 11 Full Clinical Hold 2009 Partial Clinical Hold Phase II studies FDA Meeting FDA Feedback • Study doses 12mg and lower • Increased liver monitoring • Only oral program affected • Doses of 50mg and 25mg • 2 cases of Hy’s Law at 50mg only • 6mg and 12 mg • Ut

  12. Slide 12: Broad Patent Position on Proellex

    Broad Patent Position on Proellex ® ■ Off - Drug Interval • Recent issuance of patent ‘074 – expires 2027 • Relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex ® ) or Ulipristal Acetate, with an Off - Drug Interval (ODI) for the treat

  13. Slide 13: Potential Advantages of Vaginal Delivery of Telapristone

    Potential Advantages of Vaginal Delivery of Telapristone ■ Leverage vaginal - uterine local circulation – Reduce first pass hepatic metabolism – Allows for reduced systemic blood levels ■ Clinical work to date suggests good efficacy – Current data on once daily vaginal capsules – Lower systemic bloo

  14. Slide 14: Significant Market Opportunity and Investment in this Therapeutic Area

    Significant Market Opportunity and Investment in this Therapeutic Area ▪ Ulipristal Acetate ▪ Gedeon Richter product partnered with Allergan for US market ▪ On market in EU ▪ Esmya 5 mg for Tx of UF ▪ Recently completed phase III ▪ Venus II trial ▪ Publicly stated intent to file NDA in 2H17 ▪ $1 bil

  15. Slide 15: Enclomiphene for the Treatment of Secondary Hypogonadism

    Enclomiphene for the Treatment of Secondary Hypogonadism ■ NDA submitted January 2015 – CRL received November 2015 ■ EMA filing September 2016 – currently under review ■ Opinion date is anticipated in 1Q 2018 ■ Actively seeking partnering opportunities outside of the U.S. 15

  16. Slide 16: Repros: Next steps and Milestones

    Repros: Next steps and Milestones ■ Uterine fibroid and endometriosis program with vaginal delivery treatment ■ Maximize value from patent position ■ FDA feedback makes oral development unlikely ■ New management has experience and successful track record ■ Actively seeking partnering opportunities f

Repros Therapeutics — Investor Presentation (September 2017) on 6ix